Fate Therapeutics (NASDAQ:FATE - Get Free Report)'s stock had its "neutral" rating reissued by equities researchers at Wedbush in a research report issued on Thursday,Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company's stock. Wedbush's price objective would indicate a potential upside of 439.49% from the stock's previous close.
A number of other research firms have also commented on FATE. Bank of America raised Fate Therapeutics from an "underperform" rating to a "neutral" rating in a research report on Monday, November 18th. StockNews.com upgraded Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday. Eight investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $5.50.
Check Out Our Latest Report on Fate Therapeutics
Fate Therapeutics Stock Down 8.2 %
Shares of NASDAQ FATE traded down $0.08 during midday trading on Thursday, reaching $0.93. The company had a trading volume of 2,271,640 shares, compared to its average volume of 2,565,236. The stock has a market cap of $106.21 million, a PE ratio of -0.56 and a beta of 2.26. Fate Therapeutics has a one year low of $0.88 and a one year high of $8.44. The firm's fifty day moving average price is $1.36 and its 200-day moving average price is $2.35.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $1.57 million. As a group, equities research analysts expect that Fate Therapeutics will post -1.63 EPS for the current year.
Insider Activity
In related news, Director Redmile Group, Llc acquired 397,964 shares of Fate Therapeutics stock in a transaction that occurred on Friday, December 20th. The stock was bought at an average price of $1.68 per share, with a total value of $668,579.52. Following the transaction, the director now directly owns 12,884,277 shares in the company, valued at approximately $21,645,585.36. This represents a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.00% of the company's stock.
Institutional Trading of Fate Therapeutics
Institutional investors have recently bought and sold shares of the company. Graham Capital Management L.P. bought a new stake in shares of Fate Therapeutics in the 4th quarter worth $37,000. China Universal Asset Management Co. Ltd. bought a new stake in Fate Therapeutics during the fourth quarter valued at approximately $40,000. Brevan Howard Capital Management LP purchased a new stake in shares of Fate Therapeutics in the 4th quarter worth $41,000. FPC Investment Advisory Inc. bought a new stake in Fate Therapeutics during the fourth quarter valued at about $44,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Fate Therapeutics in the fourth quarter worth about $55,000. 97.54% of the stock is owned by hedge funds and other institutional investors.
Fate Therapeutics Company Profile
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Articles

Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.